PDS Biotechnology Corporation announced that the U.S. Patent Office has issued a Notice of Allowance for its lead asset, PDS0101. The forthcoming patent, titled "Methods and Compositions Comprising Cationic Lipids for Stimulating Type I Interferon Genes" (U.S. Application No. 16/210,750), will provide broad composition and method of use claims. Combined with anticipated biologics exclusivity, this is expected to offer approximately twenty years of market protection for PDS0101, which is currently being evaluated in a Phase 3 clinical trial for HPV16-positive head and neck cancers.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PDS Biotechnology Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9630037-en) on January 22, 2026, and is solely responsible for the information contained therein.